UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.774

Sortiert nach

Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations

Gene therapy, 2017-09, Vol.24 (9), p.539-541

2017

Volltextzugriff (PDF)

Real-world data in oncology: a questionnaire-based analysis of the academic research landscape examining the policies and experiences of the cancer cooperative groups

ESMO open, 2023-04, Vol.8 (2), p.100878-100878, Article 100878

2023

Volltextzugriff (PDF)

Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders

Frontiers in pharmacology, 2022-05, Vol.13, p.775217-775217

2022

Volltextzugriff (PDF)

Comparing Discrete Choice Experiment with Swing Weighting to Estimate Attribute Relative Importance: A Case Study in Lung Cancer Patient Preferences

Medical decision making, 2024-02, Vol.44 (2), p.203-216

2024

Volltextzugriff (PDF)

A comparative analysis of orphan designations for rare neoplastic disorders versus other rare indications

European journal of cancer (1990), 2017-02, Vol.72, p.S115-S116

2017

Volltextzugriff (PDF)

Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting

Acta gastro-enterologica belgica, 2022-10, Vol.85 (4), p.557-564

2022

Volltextzugriff (PDF)

Insights In European Drug Shortages: A Survey Of Hospital Pharmacists

Value in health, 2014-05, Vol.17 (3), p.A14-A14

2014

Volltextzugriff (PDF)

A Call to Monitor Drug Shortages and the Role of Market Attractiveness in European Countries

Value in health, 2014-05, Vol.17 (3), p.A98-A98

2014

Volltextzugriff (PDF)

Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework

FEMS microbiology letters, 2016-02, Vol.363 (4), p.fnv241

2016

Volltextzugriff (PDF)

Bacteriophage therapy: Fast-forward to the past lessons identified from the advanced therapy regulation

Burns, 2016-02, Vol.42 (1), p.11-12

2016

Volltextzugriff (PDF)

HPR216 Multi-Stakeholder Perspectives on Interpretation, Challenges, and Ways Forward for the Unmet Medical Need Concept – Semi-Structured Interviews

Value in health, 2023-12, Vol.26 (12), p.S290

2023

Volltextzugriff (PDF)

Market access of Spinraza

Gene therapy, 2017-09, Vol.24 (9), p.539

2017

Volltextzugriff (PDF)

Market Access of Cancer Drugs in European Countries: A Matter of Setting Priorities for Resource Allocation

Value in health, 2013-11, Vol.16 (7), p.A427-A427

2013

Volltextzugriff (PDF)

HPR209 The Unmet Medical Needs Concept – A Structured Analysis of Its Application in Authorisation and Belgian Reimbursement Practices

Value in health, 2022-12, Vol.25 (12), p.S271-S271

2022

Volltextzugriff (PDF)

RWD93 The Experience of Cancer Cooperative Groups With Real-World Data Research: Insights From an EORTC Survey

Value in health, 2022-12, Vol.25 (12), p.S466-S467

2022

Volltextzugriff (PDF)

HPR138 How Are Patient Experience Data Reported in Regulatory Evaluation of Medicinal Products? A Document Analysis of European Public Assessment Reports

Value in health, 2023-12, Vol.26 (12), p.S278

2023

Volltextzugriff (PDF)

HPR59 Evolving Global Regulatory Landscape for Approval of Biosimilars: A Structured Literature Review on Current Challenges and Future Considerations

Value in health, 2023-12, Vol.26 (12), p.S263-S264

2023

Volltextzugriff (PDF)

PCN250 Analysis of the Characteristics and Impact of EORTC Treatment Optimization Studies Performed over Four Decades in Breast, Lung and Colorectal Cancer

Value in health, 2020-12, Vol.23, p.S467-S467

2020

Volltextzugriff (PDF)

HTA121 Opportunities and Challenges of Cross-Country Collaborations in Market Access of Medicines: Stakeholder Perspectives on the BeNeLuxA Initiative

Value in health, 2022-12, Vol.25 (12), p.S319-S320

2022

Volltextzugriff (PDF)

HSD68 Barriers and Facilitators of Shared Decision Making in Clinical Practice: An Umbrella Review

Value in health, 2022-12, Vol.25 (12), p.S287-S287

2022

Volltextzugriff (PDF)

HPR144 TNF-Alfa Inhibitor Biosimilars: Qualitative Analysis of Uptake Determinants in Southern European Hospital Markets

Value in health, 2022-12, Vol.25 (12), p.S258-S258

2022

Volltextzugriff (PDF)

HPR102 Exploring Alternative Financing Models and Early Access Schemes for Orphan Drugs: A Belgian Case Study

Value in health, 2022-12, Vol.25 (12), p.S250-S250

2022

Volltextzugriff (PDF)

HPR127 Managing Uncertainty for the Orphans: A Belgian Perspective on Managed Entry Agreements for Orphan Drugs

Value in health, 2022-12, Vol.25 (12), p.S255-S255

2022

Volltextzugriff (PDF)

HPR52 TNF-Alfa Inhibitor Therapies: Evaluating the Impact of Biosimilars Competition in Italy, Portugal and Spain

Value in health, 2022-12, Vol.25 (12), p.S242-S242

2022

Volltextzugriff (PDF)

POSA407 Perceptions of Clinicians on the Use of Real-World Evidence in Oncology: An EORTC Survey

Value in health, 2022-01, Vol.25 (1), p.S252-S253

2022

Volltextzugriff (PDF)

1 – 25 von 1.774

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.464)
Mit Volltextzugriff
(1.605)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.002)
Life Sciences & Biomedicine
(791)
Humans
(467)
Biological And Medical Sciences
(232)
Female
(215)
Male
(202)
Fundamental And Applied Biological Sciences. Psychology
(186)
Adult
(164)
Microbiology
(150)
Physical Sciences
(148)
Neurosciences & Neurology
(131)
Neurosciences
(121)
Animals
(110)
Middle Aged
(107)
Social Sciences
(89)
Science & Technology - Other Topics
(79)
Physics
(78)
Pharmacology & Pharmacy
(76)
Patients
(75)
Multidisciplinary Sciences
(73)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations

Real-world data in oncology: a questionnaire-based analysis of the academic research landscape examining the policies and experiences of the cancer cooperative groups

Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders

Comparing Discrete Choice Experiment with Swing Weighting to Estimate Attribute Relative Importance: A Case Study in Lung Cancer Patient Preferences

A comparative analysis of orphan designations for rare neoplastic disorders versus other rare indications

Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting

Insights In European Drug Shortages: A Survey Of Hospital Pharmacists

A Call to Monitor Drug Shortages and the Role of Market Attractiveness in European Countries

Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework

Bacteriophage therapy: Fast-forward to the past lessons identified from the advanced therapy regulation

HPR216 Multi-Stakeholder Perspectives on Interpretation, Challenges, and Ways Forward for the Unmet Medical Need Concept – Semi-Structured Interviews

Market access of Spinraza

Market Access of Cancer Drugs in European Countries: A Matter of Setting Priorities for Resource Allocation

HPR209 The Unmet Medical Needs Concept – A Structured Analysis of Its Application in Authorisation and Belgian Reimbursement Practices

RWD93 The Experience of Cancer Cooperative Groups With Real-World Data Research: Insights From an EORTC Survey

HPR138 How Are Patient Experience Data Reported in Regulatory Evaluation of Medicinal Products? A Document Analysis of European Public Assessment Reports

HPR59 Evolving Global Regulatory Landscape for Approval of Biosimilars: A Structured Literature Review on Current Challenges and Future Considerations

PCN250 Analysis of the Characteristics and Impact of EORTC Treatment Optimization Studies Performed over Four Decades in Breast, Lung and Colorectal Cancer

HTA121 Opportunities and Challenges of Cross-Country Collaborations in Market Access of Medicines: Stakeholder Perspectives on the BeNeLuxA Initiative

HSD68 Barriers and Facilitators of Shared Decision Making in Clinical Practice: An Umbrella Review

HPR144 TNF-Alfa Inhibitor Biosimilars: Qualitative Analysis of Uptake Determinants in Southern European Hospital Markets

HPR102 Exploring Alternative Financing Models and Early Access Schemes for Orphan Drugs: A Belgian Case Study

HPR127 Managing Uncertainty for the Orphans: A Belgian Perspective on Managed Entry Agreements for Orphan Drugs

HPR52 TNF-Alfa Inhibitor Therapies: Evaluating the Impact of Biosimilars Competition in Italy, Portugal and Spain

POSA407 Perceptions of Clinicians on the Use of Real-World Evidence in Oncology: An EORTC Survey

Suchergebnisse filtern